Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Opthea Limited
  6. Summary
    OPT   AU000000OPT2

OPTHEA LIMITED

(OPT)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 12/03
1.105 AUD   0.00%
11/09Notification regarding unquoted securities - OPT
PU
11/08AusBiotech - Mr Geoffrey Kempler announced as new AusBiotech Chair
AQ
10/26Opthea Granted Chinese Patent for Eye Disorder Drug
MT
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
1.215 1.195 1.15 1.105 1.105 Last
149033 283815 470718 589993 657222 Volume
+0.41% -1.65% -3.77% -3.91% 0.00% Change
Estimated financial data (e)
Sales 2022 0,29 M 0,20 M 0,20 M
Net income 2022 -85,5 M -59,9 M -59,9 M
Net cash position 2022 87,0 M 60,9 M 60,9 M
P/E ratio 2022 -4,42x
Yield 2022 -
Sales 2023 0,31 M 0,22 M 0,22 M
Net income 2023 -117 M -81,8 M -81,8 M
Net cash position 2023 100 M 70,1 M 70,1 M
P/E ratio 2023 -3,20x
Yield 2023 -
Capitalization 388 M 272 M 272 M
EV / Sales 2022 1 047x
EV / Sales 2023 922x
Nbr of Employees -
Free-Float 88,0%
More Financials
Company
Opthea Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing therapies primarily for eye diseases. The Company's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company's technology... 
More about the company
Ratings of Opthea Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about OPTHEA LIMITED
11/09Notification regarding unquoted securities - OPT
PU
11/08AusBiotech - Mr Geoffrey Kempler announced as new AusBiotech Chair
AQ
10/26Opthea Granted Chinese Patent for Eye Disorder Drug
MT
10/26Opthea Granted Chinese Patent Covering OPT-302 - Form 6-K
PU
10/26Opthea Unit Awarded Chinese Patent for Eye Disease Drug Candidate
MT
10/26Opthea Granted Chinese Patent Covering OPT-302
AQ
10/20OPTHEA : Chairman's Address to the 2021 Annual General Meeting - Form 6-K
PU
10/19OPTHEA : Starts Enrolling Patients in Asia-Pacific for Neovascular Macular Degeneration Dr..
MT
10/19Opthea Limited Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShOR..
CI
10/19Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and CO..
GL
10/05OPTHEA : Begins Patient Recruitment in Europe for Phase Three Retina Drug Trial
MT
10/04OPTHEA : Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD T..
PU
10/04OPTHEA : Begins Enrollment in Phase 3 Trials of OPT-302 in Wet Age-Related Macular Degener..
MT
10/04OPTHEA : Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD T..
AQ
10/04Opthea Limited Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST ..
CI
More news
News in other languages on OPTHEA LIMITED
10/26Opthea obtient un brevet chinois pour un médicament contre les troubles oculaires
10/19Opthea commence à recruter des patients en Asie-Pacifique pour des essais de médicament..
10/05Opthea commence à recruter des patients en Europe pour l'essai de phase trois du médica..
08/30Opthea creuse sa perte pour l'exercice 21 en raison de la hausse des coûts
08/09Opthea étend au Canada les essais de phase 3 de l'OPT-302 dans la dégénérescence macula..
More news
Analyst Recommendations on OPTHEA LIMITED
More recommendations
Chart OPTHEA LIMITED
Duration : Period :
Opthea Limited Technical Analysis Chart | OPT | AU000000OPT2 | MarketScreener
Technical analysis trends OPTHEA LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,11 AUD
Average target price 2,84 AUD
Spread / Average Target 157%
EPS Revisions
Managers and Directors
Megan Baldwin Chief Executive Officer, Executive Director & MD
Karen Adams Secretary & Vice President-Finance
Jeremy Max Levin Chairman
Ian Leitch Director-Clinical Research
Annette Leahy Director-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
OPTHEA LIMITED-42.45%272
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298